TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27272748

Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 932

Group type: COMPARATOR
Intervention: Tobacco smokers
Number of subjects: 932

Group type: COMPARATOR
Intervention: Dual users
Number of subjects: 932

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Dual users continuing or converting from tobacco smoking to dual use
Number of subjects: 932
Study: 27273066

Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning (SBML)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditionally trained residents
Number of subjects: 112

Group type: COMPARATOR
Intervention: Hospitalist physicians
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: SBML-trained residents
Number of subjects: 112
Study: 27273748

Group type: EXPERIMENTAL
Intervention: Large bottle (≥6 oz)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Regular bottle (<6 oz)
Number of subjects: 386
Study: 27273860

Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous rtPA (0.9mg/kg)
Number of subjects: 40
Study: 27275632

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy.
Number of subjects: 22
Study: 27276397

Group type: EXPERIMENTAL
Intervention: Percutaneous hydrodiscectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open microdiscectomy
Number of subjects: 40
Study: 27276526

Group type: EXPERIMENTAL
Intervention: Striatum involvement in anxiety circuitry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral processes related to anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schematic representation of anxiety circuitry
Number of subjects: 0
Study: 27276561

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1540
Study: 27278468

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program
Number of subjects: 30
Study: 27278794

Group type: EXPERIMENTAL
Intervention: Influenza respiratory disease broadly defined
Number of subjects: 28516

Group type: EXPERIMENTAL
Intervention: Influenza B hospitalisations
Number of subjects: 28516

Group type: EXPERIMENTAL
Intervention: Influenza prevention or early intervention with anti-viral treatment
Number of subjects: 28516

Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccination
Number of subjects: 28516
Study: 27279247

Group type: EXPERIMENTAL
Intervention: Jejunal glucose administration
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gastric glucose administration
Number of subjects: 13
Study: 27280017

Group type: EXPERIMENTAL
Intervention: Anticoagulants (specific type not mentioned, but includes vitamin K antagonists such as warfarin and newer drugs like Xa and thrombin inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27280505

Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction (AWR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (patients with intact abdominal wall undergoing colorectal resection)
Number of subjects: 18
Study: 27280591

Group type: EXPERIMENTAL
Intervention: WHO growth standards/references
Number of subjects: 5996

Group type: COMPARATOR
Intervention: National growth references
Number of subjects: 5996
Study: 27280802

Group type: EXPERIMENTAL
Intervention: Multilayer Flow Modulator (MFM)
Number of subjects: 23
Study: 27280963

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50-100mg/day for 8 weeks
Number of subjects: 36
Study: 27281556

Group type: EXPERIMENTAL
Intervention: Letrozole with lapatinib
Number of subjects: 821

Group type: COMPARATOR
Intervention: Letrozole monotherapy
Number of subjects: 821

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 821
Study: 27281773

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT-imaged subclinical arterial inflammation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TBR of each separate segment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Multiple linear regression model including age, sex, BMI, hemoglobin A1c (HbA1c), hs-CRP, cholesterol, cSBP, and PWV
Number of subjects: 44
Study: 27281793

Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 21
Study: 27282141

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Eotaxin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor alpha (TNF-α)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interferon-γ (IFN-γ)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Macrophage inflammatory protein-1α (MIP-1α)
Number of subjects: 31
Study: 27282289

Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours before chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasting for 48 hours before chemotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasting for 72 hours before chemotherapy
Number of subjects: 20
Study: 27282431

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy
Number of subjects: 345

Group type: COMPARATOR
Intervention: Basic implementation strategy
Number of subjects: 345
Study: 27282451

Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm for pre-operative prediction of anastomotic leakage (AL) risk using inflammatory, immune-related, and genetic parameters.
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Post-operative diagnostic algorithm for anastomotic leakage (AL).
Number of subjects: 588

Group type: COMPARATOR
Intervention: Patients developing anastomotic leakage (AL) post-surgery (estimated 8-10%).
Number of subjects: 588
Study: 27282601

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 35
Study: 27282899

Group type: EXPERIMENTAL
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonepicardial disease and diffuse atherosclerosis
Number of subjects: 0
Study: 27282998

Group type: EXPERIMENTAL
Intervention: FCGR3A VV genotype
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: FCGR3A VF genotype
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: FCGR3A FF genotype
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: FCGR2A (per R allele)
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: FCGRIIA RR genotype
Number of subjects: 1134
Study: 27283860

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 57
Study: 27284271

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings (GCS) plus anticoagulation (edoxaban or enoxaparin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulation alone (edoxaban or enoxaparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation plus GCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 0
Study: 27285281

Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (1-2200 mg, Q3W, Q2W, QW)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (≥1700 mg Q3W)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PankoMab-GEX
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PankoMab-GEX (≥700 mg over 3 weeks)
Number of subjects: 74
Study: 27285295

Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction of 0.25-0.5
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction greater than 0.5
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Per 0.1 BMI-SDS reduction
Number of subjects: 1388
Study: 27286368

Group type: EXPERIMENTAL
Intervention: Bipolarity Index (BPx)
Number of subjects: 615
Study: 27286790

Group type: EXPERIMENTAL
Intervention: BEZ235 (400 mg b.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BEZ235 (200 mg b.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BEZ235 (300 mg b.i.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BEZ235 (all doses)
Number of subjects: 10
Study: 27287231

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 85
Study: 27287512

Group type: EXPERIMENTAL
Intervention: ONCOS-102 (Ad5/3-D24-GM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ONCOS-102 with standard of care chemotherapy (Pemetrexed, Cisplatin, Carboplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care chemotherapy (Pemetrexed, Cisplatin, Carboplatin) alone
Number of subjects: 0
Study: 27287851

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus Asunaprevir (ASV) for 24 weeks
Number of subjects: 222
Study: 27287911

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (naïve-to-bypass)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conversion from gastric banding to gastric bypass (band-to-bypass)
Number of subjects: 134
Study: 27288210

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil 600 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil 1200 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil 600 mg and 1200 mg
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 27288278

Group type: EXPERIMENTAL
Intervention: hsTnI algorithm
Number of subjects: 3128

Group type: EXPERIMENTAL
Intervention: hsTnT algorithm
Number of subjects: 3128
Study: 27288959

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the medial forebrain bundle (MFB)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study: 27289552

Group type: EXPERIMENTAL
Intervention: Detection of chemoresistant circulating tumour cells (CTCs) after adjuvant chemotherapy
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Detection of chemoresistant circulating tumour cells (CTCs) after neoadjuvant chemotherapy
Number of subjects: 350
Study: 27291075

Group type: EXPERIMENTAL
Intervention: Hispanic caregivers
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Black, non-Hispanic caregivers
Number of subjects: 864
Study: 27291511

Group type: EXPERIMENTAL
Intervention: Aggressive ICD programming with lower VF detection zone, no antitachycardia pacing therapies during capacitor charge, and shorter detection times.
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Patients with ES
Number of subjects: 1319
Study: 27292016

Group type: EXPERIMENTAL
Intervention: Device intervention
Number of subjects: 10000000

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10000000
Study: 27293200

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (non-surgical)
Number of subjects: 24
Study: 27293875

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitreous surgery or Ahmed valve implantation
Number of subjects: 18
Study: 27294305

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg qd
Number of subjects: 36
Study: 27294708

Group type: EXPERIMENTAL
Intervention: Clickamico app (6-minute video with clown physicians)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard informative intervention
Number of subjects: 40
Study: 27294768

Group type: EXPERIMENTAL
Intervention: Hula-based intervention with self-care education
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 55
Study: 27294995

Group type: EXPERIMENTAL
Intervention: RA Activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Upper-Limb Activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Timed Activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Physical Autonomy Activities
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Physical Conditions for Activities
Number of subjects: 81
Study: 27296200

Group type: EXPERIMENTAL
Intervention: Preprocedural high-sensitivity cardiac troponin T (hs-cTnT) elevation (above 14 ng/L)
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Normal preprocedural hs-cTnT (below 14 ng/L)
Number of subjects: 2029
Study: 27296239

Group type: EXPERIMENTAL
Intervention: Baseline R-wave amplitudes ≤2.5 mV during follow-up of patients with ICDs
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Baseline R-wave amplitudes ≥2.2 to <7 mV
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Baseline R-wave amplitudes ≥17 mV
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Baseline R-wave amplitudes ≥12 to <17 mV
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: Baseline R-wave amplitudes ≥7 to <12 mV
Number of subjects: 2507
Study: 27296315

Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0
Study: 27296397

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan) 200 mg twice daily for 4 to 6 weeks
Number of subjects: 8442

Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily for 2 weeks
Number of subjects: 8442

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Number of subjects: 8442

Group type: EXPERIMENTAL
Intervention: Weighted analysis of randomized treatment
Number of subjects: 8442
Study: 27296781

Group type: EXPERIMENTAL
Intervention: Focal iodine-125 seed brachytherapy (144 Gy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard seed implant (for one patient due to bilateral disease)
Number of subjects: 20
Study: 27297010

Group type: EXPERIMENTAL
Intervention: Clinical vignette actions by doctors
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clinical vignette actions by midwives
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clinical vignette actions by other cadres (health assistants, health extension workers)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hospital facility type
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clinic facility type
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Average annual workload per skilled birth attendant
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall competence assessment
Number of subjects: 64
Study: 27297409

Group type: EXPERIMENTAL
Intervention: Eosinophils from asthmatic subjects
Number of subjects: 18

Group type: COMPARATOR
Intervention: Eosinophils from healthy subjects
Number of subjects: 18
Study: 27297785

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 17743

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 17743

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 17743
Study: 27297790

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (151 matched controls)
Number of subjects: 43
Study: 27297981

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 955
Study: 27298069

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control for baseline PROMs, septal deviation, steroid-dependent conditions, and medication use variables
Number of subjects: 228
Study: 27298729

Group type: EXPERIMENTAL
Intervention: One-year group multi-professional lifestyle intervention with monthly meetings at the paediatric outpatient obesity clinic (n=65)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Free living phase for one year (Control group, n=72)
Number of subjects: 137
Study: 27299735

Group type: EXPERIMENTAL
Intervention: Unicirc disposable instrument under topical anesthetic and wound sealing with cyanoacrylate tissue adhesive
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open surgical circumcision under local anesthetic with suturing
Number of subjects: 75
Study: 27300170

Group type: EXPERIMENTAL
Intervention: Maraviroc intensification
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (unchanged cART regimen)
Number of subjects: 21
Study: 27300475

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide daily (acute administration)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide daily (chronic administration)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide daily (acute and chronic administration)
Number of subjects: 10
Study: 27300572

Group type: EXPERIMENTAL
Intervention: Premature ovarian insufficiency (POI)
Number of subjects: 349
Study: 27301652

Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyrone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 41
Study: 27302554

Group type: EXPERIMENTAL
Intervention: EGAP (Echelle de GrAvité de la Pharmacodépendance) score
Number of subjects: 0
Study: 27302623

Group type: EXPERIMENTAL
Intervention: Mobile-based digital intervention (smoking cessation web app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline usual care web app
Number of subjects: 0
Study: 27302659

Group type: EXPERIMENTAL
Intervention: Complete immunosuppression withdrawal (WISP-R)
Number of subjects: 12
Study: 27302980

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 102

Group type: COMPARATOR
Intervention: Formula
Number of subjects: 102
Study: 27303050

Group type: EXPERIMENTAL
Intervention: Patient categorization and scoring system based on 15 rules-based algorithms
Number of subjects: 222
Study: 27303062

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy intervention
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Educational interventions targeting pain etiology and assessment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Improved communication with health-care professionals
Number of subjects: 51
Study: 27306058

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 13
Study: 27306615

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 27307294

Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy (16 mg/kg)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 102
Study: 27307468

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 703920
Study: 27307708

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.2 mg/kg every other week for 55 weeks
Number of subjects: 14
Study: 27307726

Group type: EXPERIMENTAL
Intervention: Forced Oscillation Technique (FOT)
Number of subjects: 158
Study: 27308805

Group type: EXPERIMENTAL
Intervention: Strengthening initial and repeat maternal HIV testing and provider-initiated testing (PITC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Maternal HIV testing during pregnancy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Maternal HIV diagnosis
Number of subjects: 183

Group type: COMPARATOR
Intervention: PMTCT antiretrovirals
Number of subjects: 183

Group type: COMPARATOR
Intervention: Missed opportunities for pediatric diagnosis and linkage
Number of subjects: 183

Group type: COMPARATOR
Intervention: HIV testing among previously hospitalized children
Number of subjects: 183
Study: 27309039

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (3 g sucrose/kg body weight per day and 1 g fat/kg body weight per day for 28 days)
Number of subjects: 0
Study: 27309344

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer scaffold implanted in the spinal cord parenchyma at T12.
Number of subjects: 1
Study: 27309906

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for RARS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for CRSsNP
Number of subjects: 20
Study: 27310205

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Sequential Dose-Dense FOLFOX7 followed by FOLFIRI
Number of subjects: 284

Group type: COMPARATOR
Intervention: FOLFOX4 and FOLFOX7
Number of subjects: 284
Study: 27310229

Group type: EXPERIMENTAL
Intervention: Trait Meta-Mood Scale (TMMS)
Number of subjects: 824
Study: 27312051

Group type: EXPERIMENTAL
Intervention: SPAG5 gene copy number aberrations
Number of subjects: 5439

Group type: EXPERIMENTAL
Intervention: High SPAG5 transcript expression
Number of subjects: 5439

Group type: EXPERIMENTAL
Intervention: High SPAG5 protein expression
Number of subjects: 5439

Group type: EXPERIMENTAL
Intervention: High SPAG5 transcript and protein concentrations
Number of subjects: 5439

Group type: COMPARATOR
Intervention: Anthracycline-based adjuvant chemotherapy in oestrogen receptor-negative breast cancer with high SPAG5 protein expression
Number of subjects: 5439
Study: 27312699

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 27
Study: 27312804

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (BP)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (BP)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: History of Hypertension
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Systolic BP
Number of subjects: 696
Study: 27313054

Group type: EXPERIMENTAL
Intervention: NPWT + PMD
Number of subjects: 60

Group type: COMPARATOR
Intervention: NPWT
Number of subjects: 60
Study: 27313069

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide treatment
Number of subjects: 2
Study: 27313070

Group type: EXPERIMENTAL
Intervention: Ballard scoring
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Community health worker prematurity scorecard
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Capurro method
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Eregie method
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Bhagwat method
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Foot length <75 mm
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Birth weight <2500 g
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: Neonatal anthropometrics
Number of subjects: 1066
Study: 27313547

Group type: EXPERIMENTAL
Intervention: Transitional case management intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine follow-up by private psychiatrists or general practitioners
Number of subjects: 102
Study: 27313822

Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 302

Group type: COMPARATOR
Intervention: Cal foam
Number of subjects: 302

Group type: COMPARATOR
Intervention: BD foam
Number of subjects: 302